306 related articles for article (PubMed ID: 24998555)
21. COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.
Bhat IA; Rasool R; Qasim I; Masoodi KZ; Paul SA; Bhat BA; Ganaie FA; Aziz SA; Shah ZA
Tumour Biol; 2014 Nov; 35(11):11209-18. PubMed ID: 25113252
[TBL] [Abstract][Full Text] [Related]
22. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression.
Wang X; Sun Q; Chen C; Yin R; Huang X; Wang X; Shi R; Xu L; Ren B
Oncotarget; 2016 Feb; 7(7):8029-42. PubMed ID: 26771237
[TBL] [Abstract][Full Text] [Related]
23. MCPH1 Protein Expression in Normal and Neoplastic Lung Tissues.
Zhang J; Wu XB; Fan JJ; Mai L; Cai W; Li D; Yuan CF; Bu YQ; Song FZ
Asian Pac J Cancer Prev; 2013; 14(12):7295-300. PubMed ID: 24460291
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer.
Lin G; Sun L; Wang R; Guo Y; Xie C
J Thorac Oncol; 2014 Feb; 9(2):170-8. PubMed ID: 24419413
[TBL] [Abstract][Full Text] [Related]
25. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases.
Warnecke-Eberz U; Bollschweiler E; Drebber U; Pohl A; Baldus SE; Hoelscher AH; Metzger R
Oncol Rep; 2008 Sep; 20(3):619-24. PubMed ID: 18695914
[TBL] [Abstract][Full Text] [Related]
26. Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer.
Ping W; Jiang WY; Chen WS; Sun W; Fu XN
Asian Pac J Cancer Prev; 2013; 14(6):3613-8. PubMed ID: 23886154
[TBL] [Abstract][Full Text] [Related]
27. Decrease of PDSS2 expression, a novel tumor suppressor, in non-small cell lung cancer.
Chen P; Yu J; Knecht J; Chen Q
Cancer Epidemiol; 2013 Apr; 37(2):166-71. PubMed ID: 23312889
[TBL] [Abstract][Full Text] [Related]
28. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
Zhang Z; Guo Y
Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
[TBL] [Abstract][Full Text] [Related]
29. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.
Zhan P; Shen XK; Qian Q; Zhu JP; Zhang Y; Xie HY; Xu CH; Hao KK; Hu W; Xia N; Lu GJ; Yu LK
Med Oncol; 2012 Jun; 29(2):648-55. PubMed ID: 21519871
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
32. ROS1 copy number alterations are frequent in non-small cell lung cancer.
Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
[TBL] [Abstract][Full Text] [Related]
33. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.
Li H; Zhou RJ; Zhang GQ; Xu JP
Tumour Biol; 2013 Jun; 34(3):1807-12. PubMed ID: 23471668
[TBL] [Abstract][Full Text] [Related]
35. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis.
Berta J; Kenessey I; Dobos J; Tovari J; Klepetko W; Jan Ankersmit H; Hegedus B; Renyi-Vamos F; Varga J; Lorincz Z; Paku S; Ostoros G; Rozsas A; Timar J; Dome B
J Thorac Oncol; 2010 Aug; 5(8):1120-9. PubMed ID: 20581707
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis.
Takanami I
Oncol Rep; 2004 Oct; 12(4):849-53. PubMed ID: 15375511
[TBL] [Abstract][Full Text] [Related]
37. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
38. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.
Zhang H; Duan CJ; Chen W; Wang SQ; Zhang SK; Dong S; Cheng YD; Zhang CF
Asian Pac J Cancer Prev; 2012; 13(5):2355-62. PubMed ID: 22901222
[TBL] [Abstract][Full Text] [Related]
40. High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness.
Liu PL; Tsai JR; Hwang JJ; Chou SH; Cheng YJ; Lin FY; Chen YL; Hung CY; Chen WC; Chen YH; Chong IW
Am J Respir Cell Mol Biol; 2010 Nov; 43(5):530-8. PubMed ID: 19933377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
